Search Results for "Abbvie Headquarters"
Original Source: AbbVie to keep pharma CMO biz after spinoff from Abbott
AbbVie will keep the pharma CMO business when it splits from Abbott Laboratories and ink supply deals with its former owner.
Matching Channels
Labs are the hub of much of modern medicine, either in the hospital setting processing patients blood tests and other samples, in research institutions at many universities or in the headquarters of...
Matching News
AbbVie Aims For $1 Billion Sales In Japan By 2020
Gary M. Winer, the president and CEO of the Japanese subsidiary of the newly formed AbbVie G.K. with headquarters in Tokyo, said in a Mixonline interview the company aims to increase its domestic sale...
AbbVie Sues EMA Over Trial Data
If you had any doubt that Abbott, now Abbvie, was quite serious about legally protecting its trade secrets. Think again. AbbVie is suing the EMA to prevent possible sharing of its trial data in suppor...
AbbVie Inc. (NYSE:ABBV) disclosed in an SEC filing that SVP and CSO John Leonard will retire in the "next few months." AbbVie said Leonard will be involved in the transition process for naming his suc...
BRIEF-Galapagos announces $50m extension to AbbVie deal
BRUSSELS, May 17 (Reuters) - Galapagos NV : * AbbVie and Galapagos extend GLPG0634 collaboration to include crohn's disease * Says AbbVie to pay Galapagos $50 million upon successful completion, expec...
AbbVie to Host First-Quarter Earnings Conference Call
NORTH CHICAGO, Ill., April 8, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2013 financial results on Friday, April 26, 2013, before the market opens. AbbVie will host a li...
Receptos, AbbVie partner for AbbVie's IL-13 mAb
Receptos Inc. (San Diego, Calif.) licensed from AbbVie Inc. (NYSE:ABBV) RPC4046, a humanized mAb against IL-13 that has completed Phase I testing. Receptos will conduct a Phase II trial of RPC4046 to...
Abbott board prepares way for AbbVie split off
US health care giant Abbott Laboratories (NYSE: ABT) says that its board of directors has approved the separation of its research-based pharmaceuticals business, which will be known as AbbVie Inc, and...
AbbVie: The Abbott Spinoff Arrives, But What’s Next?
It is now official – AbbVie exists. For those who may not recall, AbbVie is the so-called research-based pharma that has been spun off by Abbott Laboratories and features a portfolio of existing...
Matching PubMed Articles
Statistical methods and tool for cut point analysis in immunogenicity assays.
Administration of biopharmaceutical products can generate immune response that may severely impact the safety or efficacy of the products. Immunogenicity evaluation, required by regulatory agencies, r...
The value of certification and the CIC credential.
BACKGROUND: The American Red Cross began preferentially distributing plasma from male donors in 2007 and subsequently observed an 80% decrease in reported cases of transfusion-related acute lung injur...
Asbestos is still with us: repeat call for a universal ban.
Knowledge creation and reliable decision-making in complex emergencies.
This paper examines how the creation of knowledge and the location of decision-making authority within relief organisations influence coordination. Information was collected from the headquarters of i...
